VRTX Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of 34.76% compared to Vertex Pharmaceuticals, Inc.'s net margin of 31.72%. Vertex Pharmaceuticals, Inc.'s return on equity of 22.13% beat Eli Lilly & Co.'s return on equity of 106.26%.

Vertex Pharmaceuticals, Inc. has a consensus price target of $514.32, signalling upside risk potential of 9.45%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,133.93 which suggests that it could grow by 9.33%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Vertex Pharmaceuticals, Inc. has a beta of 0.310, which suggesting that the stock is 69.005% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Vertex Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Vertex Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals, Inc. quarterly revenues are $3.1B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Vertex Pharmaceuticals, Inc.'s net income of $1.1B is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Vertex Pharmaceuticals, Inc.'s price-to-earnings ratio is 33.12x while Eli Lilly & Co.'s PE ratio is 51.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals, Inc. is 10.38x versus 15.91x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 34.76% compared to Vertex Pharmaceuticals, Inc.'s net margin of 33.68%. Vertex Pharmaceuticals, Inc.'s return on equity of 22.13% beat Merck & Co., Inc.'s return on equity of 39.63%.

Vertex Pharmaceuticals, Inc. has a consensus price target of $514.32, signalling upside risk potential of 9.45%. On the other hand Merck & Co., Inc. has an analysts' consensus of $117.48 which suggests that it could grow by 6.54%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Vertex Pharmaceuticals, Inc. has a beta of 0.310, which suggesting that the stock is 69.005% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Vertex Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.98% to investors and pays a quarterly dividend of $0.85 per share. Vertex Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals, Inc. quarterly revenues are $3.1B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Vertex Pharmaceuticals, Inc.'s net income of $1.1B is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Vertex Pharmaceuticals, Inc.'s price-to-earnings ratio is 33.12x while Merck & Co., Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals, Inc. is 10.38x versus 4.35x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 34.76% compared to Vertex Pharmaceuticals, Inc.'s net margin of 21.32%. Vertex Pharmaceuticals, Inc.'s return on equity of 22.13% beat Pfizer Inc.'s return on equity of 10.84%.

Vertex Pharmaceuticals, Inc. has a consensus price target of $514.32, signalling upside risk potential of 9.45%. On the other hand Pfizer Inc. has an analysts' consensus of $28.82 which suggests that it could grow by 8.86%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Vertex Pharmaceuticals, Inc. has a beta of 0.310, which suggesting that the stock is 69.005% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Vertex Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.51% to investors and pays a quarterly dividend of $0.43 per share. Vertex Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Vertex Pharmaceuticals, Inc. quarterly revenues are $3.1B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Vertex Pharmaceuticals, Inc.'s net income of $1.1B is lower than Pfizer Inc.'s net income of $3.6B. Notably, Vertex Pharmaceuticals, Inc.'s price-to-earnings ratio is 33.12x while Pfizer Inc.'s PE ratio is 15.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals, Inc. is 10.38x versus 2.40x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 34.76% compared to Vertex Pharmaceuticals, Inc.'s net margin of 21.74%. Vertex Pharmaceuticals, Inc.'s return on equity of 22.13% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Vertex Pharmaceuticals, Inc. has a consensus price target of $514.32, signalling upside risk potential of 9.45%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $842.42 which suggests that it could grow by 12.75%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Vertex Pharmaceuticals, Inc. has a beta of 0.310, which suggesting that the stock is 69.005% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Vertex Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.88 per share. Vertex Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals, Inc. quarterly revenues are $3.1B, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Vertex Pharmaceuticals, Inc.'s net income of $1.1B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Vertex Pharmaceuticals, Inc.'s price-to-earnings ratio is 33.12x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals, Inc. is 10.38x versus 5.62x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.